Novo Nordisk, the Danish pharmaceutical company behind the weight-loss injection Wegovy, plans to intensify its efforts in India, positioning the drug as the only obesity therapy backed by strong evidence of cardiovascular and kidney benefits.

The company’s corporate vice president and India managing director, Vikrant Shrotriya, told India Today that Wegovy’s broader push follows a major price reduction aimed at improving accessibility.

Earlier this week, Novo Nordisk announced a 37% price cut across all dosage strengths of Wegovy, bringing its weekly cost for the starting dose down to Rs 2,712.

According to Shrotriya, the decision was driven by patient feedback and designed to make obesity treatment more affordable and sustainable.

Wegovy was introduced in India in June, two months af

See Full Page